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Abstract
Aim: Familial hypercholesterolemia (FH) patients are at high risk for premature coronary heart disease (CHD).
Despite the use of statins, most patients do not achieve an optimal LDL-cholesterol goal. The aims of this study are
to describe baseline characteristics and to evaluate Lipid Lowering Therapy (LLT) in FH patients recruited in
SAFEHEART.
Methods and Results: A cross-sectional analysis of cases recruited in the Spanish FH cohort at inclusion was
performed. Demographic, lifestyle, medical and therapeutic data were collected by specific surveys. Blood samples
for lipid profile and DNA were obtained. Genetic test for FH was performed through DNA-microarray. Data from
1852 subjects (47.5% males) over 19 years old were analyzed: 1262 (68.1%, mean age 45.6 years) had genetic
diagnosis of FH and 590 (31.9%, mean age 41.3 years) were non-FH. Cardiovascular disease was present in 14% of
FH and in 3.2% of non-FH subjects (P < 0.001), and was significantly higher in patients carrying a null mutation
compared with those carrying a defective mutation (14.87% vs. 10.6%, respectively, P < 0.05). Prevalence of current
smokers was 28.4% in FH subjects. Most FH cases were receiving LLT (84%). Although 51.5% were receiving
treatment expected to reduce LDL-c levels at least 50%, only 13.6% were on maximum statin dose combined with
ezetimibe. Mean LDL-c level in treated FH cases was 186.5 mg/dl (SD: 65.6) and only 3.4% of patients reached and
LDL-c under 100 mg/dl. The best predictor for LDL-c goal attainment was the use of combined therapy with statin
and ezetimibe.
Conclusion: Although most of this high risk population is receiving LLT, prevalence of cardiovascular disease and
LDL-c levels are still high and far from the optimum LDL-c therapeutic goal. However, LDL-c levels could be
reduced by using more intensive LLT such as combined therapy with maximum statin dose and ezetimibe.
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Background
Heterozygous familial hypercholesterolemia (FH) is the
most common genetic disorder associated with the
development of premature CHD with an autosomal
dominant mode of inheritance, and a prevalence of one
case in 400 to 500 in the general population [1]. The
disorder is caused by mutations in the gene that
encodes the low-density lipoprotein receptor (LDL-r),
leading to an increase in plasma low-density lipoprotein
cholesterol (LDL-c) levels. To date, more than 800 dif-
ferent functional mutations of the LDL-r gene have
been described worldwide, and more than 200 have
been documented in Spain [2]. Life expectancy is shor-
tened by 20 to 30 years in FH patients[3], and sudden
death and myocardial infarction are the principal causes
of death [4,5]. The genetic defect is probably the most
important factor in the clinical expression of FH; how-
ever, other genetic, environmental and metabolic factors
could play an important role in modulating the athero-
sclerotic burden in this population[6-8]. Since 1990’s,
coronary mortality and total mortality in FH patients
have markedly decreased in part due to the use of sta-
tins [9-11]. However, despite the use of statins, most of
these patients do not achieve an optimal therapeutic
LDL-c level [12] and still have a high risk for the devel-
opment of premature CHD.
The SpAnish Familial HypErcHolEsterolaemiA
CohoRt STudy (SAFEHEART), was designed to gain
insight into the prognostic factors and mechanisms that
influence the development of CHD and mortality in a
well-defined FH population. The aims of this study are
to describe baseline characteristics and to evaluate Lipid
Lowering Therapy (LLT) in FH patients recruited in
SAFEHEART.
Methods
Study Design and Subjects Recruitment
SAFEHEART is an open, multicenter, long-term pro-
spective cohort study in a well-defined FH population,
conducted in nineteen outpatient lipid clinics in Spain.
Recruitment of subjects from FH families began in
2004 and is still ongoing. Inclusion criteria are: 1)
index cases (IC) with genetic diagnosis of FH, 2) rela-
tives over 15 years old with genetic diagnosis of FH, 3)
relatives over 15 years old without a genetic diagnosis
of FH (control group). Relatives with high cholesterol
due to other causes in the control group were not
excluded.
To assure and improve the quality of data, physicians
attended to 3 different meetings where the different
questionnaires and procedures were carefully explained.
This study was approved by the local ethics committees
and all eligible subjects gave written informed consent.
Follow-up
A Coordinating Centre was created to organize and to
implement the follow-up of cases. A standardized phone
call is made every year to the subjects to know any rele-
vant changes in lifestyles, medication, and cardiovascular
events. An active epidemiological surveillance system
has been developed for the detection of fatal and non
fatal cardiovascular events that are classified according
to WHO-MONICA criteria [13].
Premature CHD is defined if one of the following
events occurs in males before 55 years old and in
females before 65 years old, 1) Myocardial infarction,
proved by at least two of the following: classic symp-
toms (> 15 minutes); specific electrocardiographic
changes; elevated cardiac enzymes (> 2× upper limit of
normal). 2) Angina pectoris, diagnosed as classic symp-
toms in combination with at least one unequivocal
result of one of the following: exercise test, nuclear scin-
tigram, dobutamine stress ultrasound scan, > 70% steno-
sis on a coronary angiogram. 3) Percutaneous coronary
intervention or other invasive procedures and coronary
artery bypass grafting.
Measures and blood samples
Demographic and clinical characteristics of subjects
include: age, educational status, medical history focused
on cardiovascular disease (CVD), classic cardiovascular
risk factors (hypertension, type 2 diabetes, smoking sta-
tus), physical examination and current treatment for
hypercholesterolemia and other risk factors. History of
CVD is obtained from medical charts provided by the
subjects at inclusion. A quality of life (SF-12) [14], food
frequency [Vázquez C, Alonso R, Garriga M, de Cos A,
de la Cruz JJ, Fuentes-Jiménez F, Mata P. Validation of
a food frequency questionnaire in Spanish patients with
Familial Hypercholesterolaemia. Nutr Metab Cardiovasc
Dis, in press] and physical activity [15] surveys are
recorded on standardized form. Physical examination
includes weight (kg), height (cm), body mass index (Kg/
m2) and waist circumference (cm). Blood pressure is
measured twice in supine position with an Omron MX3
sphyngomanometer.
Venous blood samples are taken after 12 hours of fast-
ing. Serum, plasma and DNA samples are aliquotted and
preserved at -80°C in a biobank located at the Cardio-
vascular Research Center in Barcelona. DNA is isolated
from whole blood using standard methods and the
genetic diagnosis of FH is made using a DNA-microar-
ray2 (Progenika SA, Bilbao, Spain). Serum total choles-
terol, triglycerides and HDL-cholesterol levels are
measured in a centralized laboratory using enzymatic
methods. Serum LDL-c concentration is calculated
using the Friedewald formula [16].
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Mutations were classified as receptor-negative or
receptor defective depending on their functional class as
reported previously[7]. Those mutations with non
reported functional class in the literature were classified
as “unknown”.
Lipid lowering therapy classification (LLT)
Maximum statin dose was defined as previously
described [12]: simvastatin 80 mg/day, pravastatin 40
mg/day, lovastatin 80 mg/day, fluvastatin 80 mg/day,
atorvastatin 80 mg/day, rosuvastatin 20-40 mg/day.
Maximum statin (MS) dose combined with ezetimibe 10
mg/day was considered as maximum combined therapy
(MCT). The following treatment was considered giving
at least a 50% reduction in LDL-c baseline-levels: sim-
vastatin 20 or 40 or 80 mg/day in combination with eze-
timibe 10 mg/day, pravastatin 40 mg/day in combination
with ezetimibe 10 mg/day, fluvastatin 80 mg/day in
combination with ezetimibe 10 mg/day, atorvastatin 40
or 80 mg/day, atorvastatin 10 or 20 mg/day in combina-
tion with ezetimibe 10 mg/day, rosuvastatin 20 or 40
mg/day and rosuvastatin 10 mg/day in combination
with ezetimibe 10 mg/day.
Statistical analysis
An initial descriptive analysis was carried out using
number of cases and percentages for qualitative
variables and mean and standard deviation for quantita-
tive variables with a normal distribution. For those
quantitative variables with a non normal distribution,
median and interquartilic-range were estimated. Com-
parisons of frequencies between qualitative variables
were carried out using the Chi-squared test. Mean
values of quantitative variables were compared with the
Student’s t-test for independent data while median
values were compared with the non-parametric median
test. The relationship between variables was considered
statistically significant if the p value < 0.05.
A binary logistic regression analysis (forward) was con-
ducted to determine the variables associated with the
attainment of an LDL-c < 100 mg/dl, including those
variables proved to be statistically significant in bivariate
analyses and possible confounders (age, gender, tobacco,
diabetes mellitus, high blood pressure, presence of CAD,
type of mutation, type of LLT). The magnitude of the
association was estimated using the adjusted odds ratio
(OR) with a confidence interval (CI) of 95%. All statistical
analyses were performed using the Statistical Package for
the Social Sciences (SPSS v 18.0, Chicago, IL, USA).
Results
Up to 2010, the study has enrolled 2078 participants
(1402 FH cases and 676 unaffected relatives from 402
families (Figure 1). Baseline clinical characteristics and
Figure 1 Recruitment of cases in the SAFEHEART study.
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lipid profile of 1852 participants between 20 to 79 years
are shown in Table 1. No data for subjects aged < 20
years are shown because no previous history of CVD
was observed. There were no differences in gender
between FH and control subjects. Mean age was 45.6
years (SD: 14.7) in FH subjects and 41.3 years old (SD:
14.7) in non FH subjects (p < 0.001).
Clinical and molecular diagnosis
Most of the IC (88.3%) and FH relatives (73.3%) have
been clinically diagnosed by the specialist. However,
25.4% of relatives with molecular diagnosis of FH (mean
age 44.8 years, SD 15.9) did not know their clinical con-
dition. Respect to genetic diagnosis, 120 different func-
tional mutations in LDL-r and Apo B genes have been
identified in this cohort and 25 mutations represent
65.0% of the cases recruited. Type of mutation was clas-
sified as receptor-negative or null mutations in 56.3% of
FH subjects, while 35.2% had defective mutations.
Classical risk factors and cardiovascular disease
Prevalence of current smokers was 28.4% in FH subjects
and 34.6% in the control group (P < 0.001). There were
no significant differences in the prevalence of type 2 dia-
betes and hypertension between both groups. HDL-c
levels were lower in FH patients compared with controls
(P < 0.001) and there were no differences between FH
subjects with null and defective LDL-r mutations (49.1
± 11.8 and 51.2 ± 14.3 mg/dl, respectively, P = 0.208).
History of CVD was present in 14.0% of FH patients,
almost 5 times the prevalence found in non-FH subjects
(p < 0.001). Coronary heart disease was the most fre-
quent CVD (93.4%) and it was premature in 80.0% of
cases. First cardiovascular event occurred earlier in
index cases (IC) compared with FH and non-FH rela-
tives (P < 0.001) (Table 1). Prevalence of cardiovascular
disease, especially CHD was higher in patients carrying
null mutations than those carrying defective mutations
in LDL-r gene (14.8% vs. 10.6% respectively, P < 0.05).
Lipid lowering therapy
At inclusion, 1056 (83.7%) FH cases (97.0% of IC and
78.0% of relatives) were receiving LLT compared to
18.8% of non-FH subjects (p < 0.001). Nearly all cases
on LLT were receiving statins (95.4%), either in mono-
therapy (58.3%) or in combined therapy (37.0%), espe-
cially with ezetimibe (31.3%). The most frequent
prescribed statins were Atorvastatin (57.3%), Simvastatin
(28.9%) and Rosuvastatin (2,9%). Mean doses of statins
were: Atorvastatin 44.8 mg (SD: 25.8), Simvastatin 40.7
mg (SD: 23.3) and Rosuvastatin 28.8 mg (SD: 12.7).
Only 13.4% of FH subjects were receiving MS dose, and
13.6% were receiving MCT.
LDL-c levels and LDL-c goal achievement
LDL-c level was not available in 91 FH cases.
Mean LDL-c level was 220.7 mg/dl (SD: 72.5) in those
FH cases that were not receiving LLT (16.3%) compared
to 186.5 mg/dl (SD: 65.6) of LDL-c level in FH cases on
LLT (83.7%). Of those FH patients receiving LLT, only
33 (3.4%) had an LDL-c level < 100 mg/dl, while 149
(15.5%) had an alternative LDL level < 130 mg/dl. On
Table 1 Baseline characteristics of subjects recruited in SAFEHEART (20 to 79 years old, N = 1852)
Index Cases N = 387 FHR (+) N = 875 FHR (-) N = 590 P-value
Gender (male)% 52.2 46.3 46.3 0.117
Mean age (years) *
(Age range)
49.1 ± 12.9
(20.2-78.0)
44.1 ± 15.2
(20.1-79.0)
41.3 ± 14.7
(20.2-78.5)
< 0.001
Previous Clinical Diagnosis of FH (%) 100 74.6 13.9 < 0.001
History of CVD (%) 21.7 10.6 3.2 < 0.001
Age of first Cardiovascular event (Age range) 42.8 ± 9.7
(24.0-67.0)
50.3 ± 11.6
(28.0-76.0)
53.9 ± 8.5
(39.0-69.0)
< 0.001
Previous LLT (%) 96.9 77.8 18.8 < 0.001
Type 2 Diabetes (%) 2.1 4.0 3.6 0.220
High Blood Pressure (%) 14.7 14.6 12.7 0.531
Tobacco (current/past)(%) 20.2/33.3 32.0/21.0 34.6/17.1 < 0.001
Xanthomas (%) 20.7 12.8 0.0 < 0.001
BMI (Kg/m2) * 26.7 ± 4.3 26.6 ± 5.00 26.2 ± 5.2 0.272
Total cholesterol (mg/dL)* 256.6 ± 71.9 264.6 ± 69.6 213.3 ± 46.4 < 0.001
Triglycerides (mg/dL)** 89.0 (52) 85.0 (56) 85.0 (54) 0.239
LDL-C (mg/dL)* 188.0 ± 69.9 193.8 ± 66.9 131.3 ± 41.4 < 0.001
HDL-C (mg/dL)* 48.6 ± 13.6 50.3 ± 13.9 51.1 ± 13.9 0.001
FH, Familial Hypercholesterolemia; FHR, Familial Hypercholesterolemia relatives; CVD, Cardiovascular Disease; LLT, Lipid lowering therapy; BMI, Body Mass Index;
LDL-C, cholesterol transported on low-density lipoproteins; HDL-C, cholesterol transported on High Density Lipoproteins. * values are expressed as Mean and
standard deviation; ** values are expressed as Median and interquartilic range.
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the other hand, 270 FH patients (29.0%) receiving com-
bined therapy (of whom 47.7% were on MCT) did not
reach LDL-c goal. Cases with an LDL-c > 160 mg/dl
and > 200 mg/dl in the MCT group were 54 (41.5%)
and 21 (16.1%), respectively. LDL-c levels in patients
using combined therapy with ezetimibe was slightly
higher but not significant in those FH subjects with
defective mutation compared with null mutation (171.2
± 67.6 vs. 161.2 ± 57.2, respectively, P = 0.227).
Characteristics of FH patients according to attain-
ment of LDL-c goal are shown in Table 2. Patients
with an LDL-c on target were older, had a higher pre-
valence of CVD history, type 2 diabetes mellitus,
hypertension, and were mostly treated with combined
therapy than those subjects not on target (p < 0.05).
The percentage of cases receiving LLT expected to
reduce LDL-c levels at least 50% was 51.5% and was
higher (63.6%) in patients on goal compared to those
patients not on target (49.9%), although this difference
was not statistically significant. However, LDL-c levels
were lower in those patients with more intensive LLT
(174.0 ± 62.2 mg/dl vs. 196.5 ± 63.8 mg/dl in patients
receiving medication to reduce LDL-C ≥50% or below,
respectively). There were no differences in LDL-c goal
attainment between cases with null and defective
mutations. The attainment of LDL-c goal was slightly
higher but not statistically significant in those cases
treated by specialists compared to general practitioners
(59.3% vs 55.2%, P = 0.677).
Logistic regression analysis showed that combined
therapy using statin and ezetimibe was significantly
associated with the achievement of LDL-c goal (OR
adjusted: 2.22; IC95%:1.10-4.48), after adjustment for
age, sex, CVD and cardiovascular risk factors.
Discussion
SAFEHEART is a long-term prospective cohort of a
molecularly well-defined FH population in Spain. The
present study shows that although most of FH cases are
on LLT, cardiovascular risk is still high, in part due to
the high LDL-c levels. An LDL-c level below 100 mg/dl
was reached by 3.4% of patients receiving treatment,
and of those patients not at target, 71% were not receiv-
ing combined therapy with ezetimibe.
Compared with other FH prospective studies [5,9-11],
this cohort establishes genetic diagnosis of all study par-
ticipants, eliminating misclassification bias when clinical
criteria that may include polygenic hypercholesterolemia
or familial combined hyperlipidemia are used. It has
been demonstrated that more than 30% of FH cases
might be classified incorrectly if only clinical diagnosis
is used compared with the use of genetic test [17]. In
this cohort, the DNA test identified 25,4% of relatives
that did not know their clinical condition, with a mean
age of 45 years, that is higher than the age recom-
mended for starting LLT in agreement with clinical
guidelines [18]. DNA testing offers a definitive and spe-
cific diagnosis and those systems based on a DNA
microarray have been demonstrated to be cost-effective
[19]. This study confirms that Spanish FH subjects are
genetically very heterogeneous as previously described
[2,7].
History of CVD was present in 14.0% of FH patients,
almost 5 times the prevalence found in non-FH subjects.
Table 2 Characteristics of FH patients on LLT classified according to attainment of LDL-c goal
LDL-Ch < 100 mg/dL (N = 33) LDL-Ch ≥ 100 mg/dL (N = 932)A P-value
Male gender, N(%) 18 (54.5) 454 (48.7) 0.510
Cases ≥ 45 years, N (%) 24 (72.7) 492 (52.8) 0.024
Age (y)* 54.7 (SD:14.5) 47.4 (SD:14.2) 0.004
History of CVD, N (%) 10 (30.3) 153 (16.4) 0.036
Type 2 Diabetes, N (%) 4 (12.1) 33 (3.5) 0.012
High Blood Pressure, N (%) 10 (30.3) 157 (16.8) 0.045
Current smokers, N (%) 5 (15.2) 239 (25.6) 0.173
BMI (Kg/m2)* 26.6 (SD:4.0) 26.7 (SD:4.6) 0.882
Control by Specialist, N (%) 16 (59.3) 293 (53.2) 0.677
Null/Defective mutations, N (%) 16/14(48.5/42.4) 541/311(58.0/33.4) 0.525
Years on statin treatment* 7.9 (SD:8.1) 6.8 (SD:6.3) 0.334
≥ 50% LDL-c reduction, N (%) 21 (63.6) 471 (49.9) 0.254
Monotherapy with Statins, N (%) 11 (33.0) 565 (60.6) 0.002
Maximum Statin dose, N (%) 1(3.0)B 134 (14.4) B 0.229
Combined Therapy, N (%)C 18 (54.5) 270 (29.0) 0.002
Maximum Therapy, N (%)D 6 (18) B 124 (13.3) B 0.238
FH, Familial hypercholesterolemia; LLT, Lipid-lowering therapy; CVD, Cardiovascular disease; BMI (Body mass index) (A) LDL-ch levels were uknown in 91 cases; (B)
percentage calculated with total cases in each group. (C) Combined therapy includes only any statin + ezetimibe 10 mg; (D), Maximum therapy includes any
statin at maximum dose + ezetimibe 10 mg; *Mean and Standard Deviation (SD).
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This high cardiovascular risk is explained in part by the
genetic background and by the presence of other cardio-
vascular risk factor such as tobacco consumption. This
study shows that FH subjects with null mutation have
higher prevalence of PCVD as previously described [7].
Prevalence of current smokers is still very high in these
subjects (28.4%) and similar to the Spanish general
population (29.5%) [20]; therefore, it is necessary to
implement appropriate early-intervention strategies
based on therapeutic and lifestyle changes, specially
focus on quitting smoking.
Another important factor that can affect the develop-
ment of CHD is related to LLT. The Simon Broom Reg-
istry showed that mortality in FH was reduced
significantly after the introduction of statins [9]. Besides,
a recent publication showed that FH patients without
clinical CVD that started statin therapy after 1990 had a
76% reduction in the risk of cardiovascular events
although the dose of statin used was lower than the
recommended in this population; however, there are no
data for LDL-c goal attainment [11].
International Guidelines consider FH patients at high
cardiovascular risk and therefore the optimal LDL-c goal
should be < 100 mg/dl [21,22] or to achieve at least a
50% reduction in LDL-c levels [18]. This study shows
that although most of FH Spanish patients are treated
with LLT, only 3.4% have an LDL-c below 100 mg/dl;
however, half of this population were receiving treatment
to reduce LDL-C ≥ 50%. The best predictor for goal
attainment was the use of combined therapy with ezeti-
mibe. A large cross-sectional study carried out in The
Netherlands showed that 21% of FH patients achieved
LDL-c goal [12]. This difference could be explained in
part because 25% of Dutch patients were on maximum
therapy, whereas this occurred only in 13.6% of Spanish
patients. On the other hand, 71% of the cases that were
not on target were not receiving combined therapy. The
use of combined therapy with ezetimibe in this cohort is
low, probably because until now there is no evidence of
the benefit on atherosclerotic burden measured as
intima-media thickness in this population [23]. However,
it has been shown that co-administration of ezetmibe
with a statin is effective in reducing the estimated risk for
cardiovascular mortality measured by the Framingham
model in hypercholesterolemic patients [24]. The recent
ezetimibe’s reimbursement approval for FH patients and
the introduction of rosuvastatin in Spain will probably
contribute to increase the attainment of LDL-c goal, or at
least a more intensive LDL-c reduction.
Although this is a cross-sectional analysis, the long-
term follow-up of this cohort will allow to determine
the role of changes in lifestyle and the further effect of a
more intensive LLT and LDL-c goal attainment in the
reduction of cardiovascular morbidity and mortality.
The results of this study show that there is still room
for improvement in FH treatment in terms of using
more combined therapy and higher doses of statins.
Conclusions
In conclusion, most of this high risk FH population still
have high LDL-c levels and did not achieve the opti-
mum LDL-c target as recommended by international
guidelines. The combination of a statin and ezetimibe
was associated with the best attainment of LDL-c goal.
There is a medical need for new LLT options in combi-
nation with current therapy to reach lower LDL-c levels
together with a better control of other risk factors to
prevent CAD in this population.
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